Last updated: April 3, 2024
Sponsor: Bristol-Myers Squibb
Overall Status: Completed
Phase
1
Condition
N/ATreatment
BMS-986447
Placebo
Clinical Study ID
NCT05760937
IM054-003
Ages 18-55 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Body mass index between 18 and 30 kilograms per metered square (kg/m^2), inclusive.
- Healthy male and female participants without clinically significant deviation fromnormal in medical history, physical examination, ECG, and clinical laboratorydeterminations.
- A negative COVID-19 test, which will be performed in the manner mandated by theclinical side where the study is being conducted, at screening and check-in Day -2.
Exclusion
Exclusion Criteria:
- Participant has any condition that confounds the ability to interpret data from thestudy.
- Participant has any condition including the presence of laboratory abnormalities,which places the participant at unacceptable risk if the participant was toparticipate in the study.
- Any major surgery or planned surgery (except gastrointestinal [GI] surgery, asdescribed below) within 12 weeks of study intervention administration. Note: Other protocol-defined inclusion/exclusion criteria apply.
Study Design
Total Participants: 32
Treatment Group(s): 2
Primary Treatment: BMS-986447
Phase: 1
Study Start date:
March 10, 2023
Estimated Completion Date:
November 27, 2023
Connect with a study center
Anaheim Clinical Trials, LLC
Anaheim, California 92801
United StatesActive - Recruiting
Local Institution - 0001
Anaheim, California 92801
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.